Reduction of adverse effects by systemic antihistamines in drug therapy with fumarates in severe chronic plaque psoriasis: a doubleblind, randomized, placebo controlled clinical trial

Reduction of adverse effects by systemic antihistamines in drug therapy with fumarates in severe chronic plaque psoriasis: a doubleblind, randomized, placebo controlled clinical trial - Reduction of adverse effects of fumarates with antihistamines.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON37148

Enrollment

Registered

2009-08-11

Start date

2009-11-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fumarates side-effects

Interventions

psoriasis vulgaris

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1)Patients with known severe psoriasis of the chronic plaque type 2)PASI >= 10 3)Age >= 18 years 4)Signed informed consent

Exclusion criteria

Exclusion criteria: 1)Pregnancy and breast feeding 2)Patients with Prostate hyperplasia, Glaucoma, Stomach ulcer 3)Patients with liver diseases 4)Patients with kidney diseases 5)Patients with blood test deviations 6)Patients with gastro-intestinal diseases 7)Patients with a history of malignancies

Design outcomes

Primary

Measure	Time frame
To attempt to decrease the side effects in patients by using fumarates in combination with antihistamines (Cetirizine).	—

Secondary

Measure	Time frame
We will attempt to show that antihistamines can also support fumarate therapy with an antipsoriatic effect through immunomodulation.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)